Overview

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Status:
Completed
Trial end date:
2013-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer